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Abstract
Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their anticancer activity is not
completely understood. The oncogenic transcription factor FoxM1 is one of the most overexpressed genes in human
tumors, while its expression is usually halted in normal non-proliferating cells. Previously, we established that thiazole
antibiotics Siomycin A and thiostrepton inhibit FoxM1 and induce apoptosis in human cancer cells. Here, we report that
Siomycin A and thiostrepton stabilize the expression of a variety of proteins, such as p21, Mcl-1, p53 and hdm-2 and also act
as proteasome inhibitors in vitro. More importantly, we also found that well-known proteasome inhibitors such as MG115,
MG132 and bortezomib inhibit FoxM1 transcriptional activity and FoxM1 expression. In addition, overexpression of FoxM1
specifically protects against bortezomib-, but not doxorubicin-induced apoptosis. These data suggest that negative
regulation of FoxM1 by proteasome inhibitors is a general feature of these drugs and it may contribute to their anticancer
properties.
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Introduction
The proteasome is a protein complex that target ubiquitin-
tagged proteins for degradation in an ATP-dependent manner.
Recent advances in the understanding of the mechanisms of
proteasome activity led to the development of proteasome
inhibitors as effective drugs against human cancer. Bortezomib
(Velcade) was the first proteasome inhibitor approved for the
treatment of multiple myeloma with potential benefits against
other types of cancer in the future. Since certain types of cancer
may rely on a functional proteasome for growth, inhibition of
proteasome activity would selectively kill these tumors [1].
However, the precise mechanisms of the anticancer activity of
proteasome inhibitors are still not well understood. Several
explanations have been presented for the antitumor properties of
proteasome inhibitors, such as NF-kB inhibition, stabilization of
p53, shift in the balance between pro- and antiapoptotic Bcl-2-
family proteins and other (reviewed in ref. [2]). Abnormal NF-kB
regulation has been shown in a variety of cancers leading to the
transcriptional activation of genes responsible for cell prolifera-
tion, inhibition of apoptosis, angiogenesis and metastasis [3].
Proteasome inhibitors hinder NF-kB transcriptional activity via
stabilization of IkB and sequestration of NF-kB in the cytoplasm
[1]. Significance of NF-kB targeting by bortezomib was validated
in multiple myeloma cells where genes that belong to NF-kB
pathway were significantly overexpressed in samples associated
with response to bortezomib [3,4]. In addition, recently it
has been proposed that the anticancer effects of proteasome
inhibition may depend on preventing the destruction of the CDK
inhibitor, p27 [5].
Forkhead box (Fox) M1, FoxM1, is a transcription factor of the
Forkhead family that induces the expression of genes involved in
cell cycle progression and maintenance of genomic stability [6]. It
has been shown that FoxM1 is strongly upregulated in a variety of
human solid tumors (reviewed in ref. [7,8]), while its expression is
suppressed in non-dividing cells [6]. The role of FoxM1 in
promoting cancer was further emphasized by the poor prognosis
for breast cancer patients with higher levels of FoxM1 gene
expression [9]. On the other hand, suppression of FoxM1
expression delayed liver tumor growth in mice [10,11] and
inhibited the metastatic potential of human pancreatic cancer cells
in vitro [12]. Since FoxM1 suppression appears to inhibit
tumorigenesis, chemical compounds that target FoxM1 may act
as anticancer drugs [13,14,15,16,17]. In our previous studies we
demonstrated that thiazole antibiotics Siomycin A and thiostrep-
ton induce apoptosis in human cancer cells and inhibit FoxM1
expression [13,17,18]. Here, we report that thiopeptides, Siomycin
A and thiostrepton also act as proteasome inhibitors. Furthermore,
we showed that well-known proteasome inhibitors such as
MG115, MG132 or Bortezomib inhibit FoxM1 transcriptional
activity and expression. We propose that negative regulation of
FoxM1 by proteasome inhibitors may contribute to their
anticancer properties.
Results and Discussion
Previously, we have shown that Siomycin A and thiostrepton
inhibit FoxM1 transcriptional activity [13,17,18]. We also
detected decrease in FoxM1 protein levels after thiopeptide
treatment [13,17,18] as a result of FoxM1 positive autoregulatory
loop [19]. However, when we evaluated the expression of other
cellular proteins following exposure to thiazole antibiotics we
found that Siomycin A treatment led to an opposite effect,
predominantly to the stabilization of a variety of proteins, such as
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6593p21, Mcl-1, p53 and hdm2 (Fig. 1A). It has been shown earlier
that these proteins are usually upregulated by proteasome
inhibitors [2,20] and we found that Siomycin A and proteasome
inhibitor MG132 stabilize the expression of these proteins in a
similar manner (Fig. 1A). This was the first evidence suggesting
that thiazole antibiotics may also inhibit proteasome activity.
Since proteasome inhibitors usually hinder the activity of NF-kB
via the stabilization of its negative regulator IkB-a [1,2] we
examined whether Siomycin A and thiostrepton inhibit NF-kB
activity. 293T cells stably expressing an NF-kB-Luc reporter
construct were treated with TNF-a and the next day with Siomycin
A or thiostrepton, and the luciferase activity was measured. We
found that both thiostrepton and Siomycin A suppress NF-kB
transcriptional activity (Fig. 1B) suggesting that thiazole antibiotics
inhibit NF-kB activity similarly to proteasome inhibitors [21].
To directly test whether the thiazole antibiotics inhibit
proteasome activity in vitro we compared them with well-known
proteasome inhibitors MG132 and lactacystin against the 20S
proteasome using the Proteasome Activity Assay Kit (Millipore/
Chemicon) (see materials and methods). We found that thiazole
antibiotics are indeed proteasome inhibitors, although not as
potent as bona-fide proteasome inhibitors, MG132 and lactacystin
(Fig. 1C). Since we demonstrated before that the thiopeptides
inhibit the transcriptional activity and the expression of FoxM1
[13,18] and here we showed that they also act as proteasome
inhibitors (Fig. 1), we decided to test the notion that other known
Figure 1. Thiazole antibiotics act as proteasome inhibitors and the known proteasome inhibitors target FoxM1. (A) Siomycin A
stabilizes protein expression similarly to proteasome inhibitor MG132. U2OS cells treated as indicated were harvested and immunoblotting
was carried out with antibodies specific for p53, p21, hdm2, Mcl-1, and b-actin. (B) Thiazole antibiotics inhibit NF-kB transcriptional activity.
293T-NF-kB-Luc cells were induced with 10 ng/mL TNF-a for 24 hrs and treated with 5 mM of the thiazole antibiotics for additional 10 hrs followed by
luciferase assay. The results shown are mean6SD of three separate experiments. (C) Inhibition of 20S proteasome activity by Siomycin A and
thiostrepton. The inhibition of proteasome activity by the thiazole antibiotics in vitro was less efficient compared with proteasome inhibitors, MG-
132 and lactacystin as detected by using 20S Proteasome activity kit (Millipore). The free AMC fluorescence was quantified at 380/460 nM in a
fluorometer (SpectraMax GeminiXS, Molecular Devices). The results shown are mean6SD of three separate experiments. (D) Proteasome
inhibitors inhibit FoxM1 transcriptional activity. C3-Luc cells were treated with a combination of 1 ug/ml doxycycline and the indicated
concentrations of the proteasome inhibitors MG115, MG132 and bortezomib (BOR). The luciferase activity was determined by using the Luciferase
Assay System (Promega) according to the manufacturer’s instructions. The results shown are mean6SD of three independent experiments. The
asterisks on each graph represent statistically significant differences with p values,0.001.
doi:10.1371/journal.pone.0006593.g001
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how proteasome inhibitors affect FoxM1 transcriptional activity
we used a derivative of U2OS osteosarcoma cell line, C3-Luc cells
with a doxycycline-inducible FoxM1-GFP fusion protein and a
firefly luciferase under the control of multiple FoxM1 response
elements [13]. Cells were treated with a combination of
doxycycline and proteasome inhibitors, and 24 hours later the
luciferase activity was measured. We confirmed that all tested
proteasome inhibitors strongly inhibited FoxM1 transcriptional
activity (Fig. 1D) similarly to the thiazole antibiotics [13,17,18].
In addition, we investigated if proteasome inhibitors suppress
FoxM1 protein expression as well. We treated U266 and
RPMI8226 multiple myeloma cells, HL-60 leukemia cells and
human U2OS-C3 osteosarcoma cells with proteasome inhibitors
MG115, MG132 and bortezomib (Fig. 2A) and analyzed the cell
lysates for the levels of FoxM1 by immunoblotting. We found that
proteasome inhibitors repress FoxM1 protein expression, suggest-
ing that they antagonize not only the transactivation ability of
FoxM1, but they also inhibit its expression (Fig. 2A) very similarly
to Siomycin A and thiostrepton [13,17,18]. Moreover, we found
by immunoblotting for cleaved caspase-3 and also by annexin V
staining that proteasome inhibitors induce apoptosis in a variety of
human cancer cell lines (Fig. 2A, B), which correlated with the
suppression of FoxM1 (Fig. 2A).
To further examine the role of FoxM1 in apoptosis induced by
proteasome inhibitors we utilized a U2OS-C3-osteosarcoma cell
line with a doxycycline-inducible FoxM1-GFP fusion protein [13]
and tested how proteasome inhibitors induce cell death in the
presence and the absence of exogenous FoxM1. FoxM1 expression
was induced with the addition of doxycycline and the following day
the cells were treated with different concentrations of bortezomib
for 24 hours (Fig. 2C). We observed that overexpression of FoxM1
protected cells against cell death induced by bortezomib as detected
by immunoblotting for cleaved caspase-3 (Fig. 2C). In contrast, we
found that FoxM1 does not protect against doxorubicin-induced
apoptosis (Fig. 2C), suggesting that FoxM1 specifically protects cells
against proteasome inhibitor-induced apoptosis. Since proteasome
inhibitors down-regulate FoxM1 and FoxM1 overexpression
protects against cell death mediated by proteasome inhibitors,
suppression of FoxM1 may be required for the anticancer activity of
these drugs. Further experiments are needed to clarify the
mechanisms of FoxM1 down-regulation by proteasome inhibitors
and the importance of FoxM1 suppression in the activity of
proteasome inhibitors as anticancer drugs.
Materials and Methods
Cell lines, media and chemical compounds
U266 and RPMI8226 multiple myeloma cell lines, and HL-60
leukemia cell line were purchased from American Type Culture
Collection and were grown in RPMI1640 medium (Invitrogen). A
U2OS clone C3 cell line with doxycycline-inducible FoxM1-GFP
fusion protein [10]; U2OS derived C3-Luc osteosarcoma cell line
stably expressing the doxycycline-inducible FoxM1-GFP and
firefly luciferase under the control of multiple FoxM1 responsive
elements [13] and 293T-NF-kB-Luc cell line stably expressing an
NF-kB-Luc reporter were grown in DMEM medium (Invitrogen).
In all cases the media were supplemented with 10% fetal bovine
serum (Atlanta Biologicals) and 1% penicillin-streptomycin
(GIBCO) and the cell lines were kept at 37uCi n5 %C O 2. Cell
lines were tested for mycoplasma contamination using MycoAlert
Mycoplasma detection kit (Lonza Rockland) and were found to be
negative. Siomycin A (NCI), thiostrepton (Sigma), doxorubicin
(Sigma), MG115 (Sigma), MG132 (Calbiochem) and bortezomib
(Velcade) (Millenium Pharmaceuticals) were dissolved in DMSO
(dimethylsulfoxide), doxycycline (Clontech) in PBS (phosphate-
buffered saline) and TNF-a (R&D Systems) in PBS containing
0.1% bovine serum albumin.
Immunoblot analysis
Cancer cells of different origin treated as indicated were
harvested and lysed by using IP buffer (20 mM HEPES, 1%
Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
100 mM NaF, 10 mM Na4P2O7, 1 mM sodium othrovanadate,
0.2 mM PMSF supplemented with protease inhibitor tablet
(Roche Applied Sciences). Protein concentration was determined
by the Bio-Rad Protein Assay (BIO-RAD). Isolated proteins were
separated on 8% or 10% SDS-PAGE and transferred to PVDF
membrane (Millipore). Immunoblotting was carried out as
described in [22,23,24] with antibodies specific for FoxM1 (a gift
from Dr. Costa’s lab), cleaved caspase-3 (Cell signaling), p53
(Santa-Cruz Biotechnology), p21 (BD-Pharmingen), hdm2 (Santa-
Cruz Biotechnology), Mcl-1 (LabVision), and b-actin (Sigma).
Luciferase assays
The derivative of U2OS osteosarcoma cell line (U2OS-C3-Luc)
was treated with a combination of 1 mg/ml doxycycline and the
indicated concentrations of the proteasome inhibitors MG115,
MG132 and bortezomib. Also, the 293T-NF-kB-Luc cell line was
stimulated with 10 ng/mL TNF-a for 24 hrs followed with 5 mMo f
Siomycin A or thiostrepton treatment for 10 hrs, respectively. The
luciferase activity was determined by using the Luciferase Assay
System (Promega) according to the manufacturer’s instructions and
data were normalized on the amount of protein in the samples.
20S proteasome activity assay
The inhibition of proteasome activity by thiazole antibiotics in vitro
was compared with that of two known proteasome inhibitors, MG-
132 and lactacystin using 20S Proteasome Activity Assay Kit
(Millipore) according to the instructions of the manufacturer. The
assay is based on the detection of the fluorophore 7-amino-4-
methylcoumarin (AMC) after cleavage from the labeled substrate
LLVY-AMC in the presence and the absence of tested compounds.
25 mM of the compounds were pre-incubated with the proteasome
samples for 15 minutes at room temperature and then the proteasome
substrate was added. Samples were incubated for 1 hour at 37uCa n d
the free AMC fluorescence was quantified at 380/460 nm in a
fluorometer (Spectra Max GeminiXS, Molecular Devices).
Annexin V-PE/7AAD staining
Control and treated cells were stained using Annexin V-PE
apoptosis detection kit (BD-Pharmingen) according to the
manufacturer’s recommendations as described in [17].
Statistical analysis
Statistical analysis was performed with Microsoft Excel using
the Student t test. P values of,0.05 were considered to be
statistically significant.
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PLoS ONE | www.plosone.org 3 August 2009 | Volume 4 | Issue 8 | e6593Figure 2. Proteasome inhibitors target FoxM1 protein and overexpression of FoxM1 partially protects cancer cell lines from
proteasome inhibitor-induced apoptosis. (A) Proteasome inhibitors induce apoptosis and inhibit FoxM1 protein expression in
multiple myeloma, leukemia and osteosarcoma cell lines. U266 and RPMI8226 multiple myeloma, HL-60 leukemia and U2OS-C3 osteosarcoma
cell lines were treated with proteasome inhibitors MG115, MG132 and bortezomib (BOR). Apoptosis was assessed by immunoblotting for cleaved
caspase-3 and FoxM1 protein levels were detected by immunoblotting. b-actin was used as the loading control. (B) Proteasome inhibitor-induced
apoptosiswasfurtherquantifiedbyusingAnnexinV-PE/7AADstaining.U266andRPMI8226multiplemyeloma,HL-60leukemiaandU2OS-C3
osteosarcoma cell lines were grown in the absence or presence of indicated concentrations of proteasome inhibitors MG115, MG132 and bortezomib
(BOR)for24 hours.FollowingdrugtreatmentcellswerestainedwithAnnexinV-PE/7AADandthenanalyzedbyflowcytometry.Percentageofapoptotic
cells is shown in brackets. Concentrations of drugs are the same as in the Fig 2A. (C) Overexpression of FoxM1 specifically protects against cell
death induced by Bortezomib. Overexpression of FoxM1 protected against cell death induced by increasing amount of bortezomib (BOR), but not
that of doxorubicin. Immunoblotting was carried out with antibodies specific for cleaved caspase-3 and b-actin.
doi:10.1371/journal.pone.0006593.g002
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